carboplatin teva 10 mg/ml
sindan - pharma s.r.l. - romania - carboplatinum - conc. pt. sol. perf. - 10mg/ml - alte antineoplazice compusi ai platinei
technescan lyomaa 2,0 mg
mallinckrodt medical b.v. - olanda - tc 99 m - macrosalb - trusa (kit) pentru preparate radiofarmaceutice - 2 mg - sistem respirator particule cu technetium pt. injectare
oxaliplatin kabi 5 mg/ml
fresenius kabi oncology plc. - oxaliplatinum - conc. pt. sol. perf. - 5mg/ml - alte antineoplazice compusi de platina
topogyne 400 micrograme
nordic pharma - olanda - misoprostolum - compr. - 400micrograme - ocitocice prostaglandine
oxaliplatin kabi 5 mg/ml
fresenius kabi deutschland gmbh - germania - oxaliplatinum - conc. pt. sol. perf. - 5mg/ml - alte antineoplazice compusi de platina
topogyne 400 micrograme
nordic pharma - olanda - misoprostolum - compr. - 400micrograme - ocitocice prostaglandine
topogyne 400 micrograme
delpharm lille sas - franta - misoprostolum - compr. - 400micrograme - ocitocice prostaglandine
leponex comprimate 100 mg
novartis pharma ag - clozapinum - comprimate - 100 mg
leponex comprimate 25 mg
novartis pharma ag - clozapinum - comprimate - 25 mg
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.